- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02032693
Everycell's Effect on DNA Damage, Inflammation, and Stress
The Effect of Dietary Supplementation on DNA Damage, Inflammation, Stress, and Related Factors Important in Somatic and Stem Cell Senescence in Healthy Adults
The investigators are conducting this research because they want to determine if a dietary supplement, called Everycell™, has an effect on the functioning of the study participants' cells. The results of this research will be used to help develop additional strategies for trying to fight the effects of aging. The primary purpose of this study is to determine the effectiveness of Everycell™ compared to placebo (a pill that does nothing) on DNA damage, inflammation, stress, and related factors. Taking Everycell™ is not a medical prescription, treatment, or cure for any known disease or condition.
Helping patients' nutritional status is important to prevent the continued worsening of chronic diseases and also to counteract the effects of aging. Americans also have difficulties with compliance to prescription medications due to their toxicity and side effects. This study aims to learn more about how a dietary supplement may improve nutritional status and enable the body to normalize cellular functioning, which may improve quality of life. The results of this research will be used to determine if Everycell™ is beneficial for overall cellular health and to counteract the effects of aging.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study is a 6-week, randomized, double-blind, placebo-controlled trial to evaluate the effect of everycell compared to placebo on DNA damage, inflammation, stress, and related factors in 30 healthy adults (18-55 years of age). Participants will be assessed at baseline, 4 weeks (end of intervention), and 6 weeks (2-week washout period), and the study will consist of two treatment arms, including: (a) Everycell and (b) placebo. Additionally, the study will examine subject health-related quality of life (QoL).
Specific Aim. Test the effect of Everycell compared to placebo on DNA damage, inflammation, stress, and related factors in a sample of healthy adults.
Hypothesis. The Everycell group will demonstrate improvements in DNA damage, inflammation, stress, and related factors at 4 and 6-week follow-ups compared to placebo.
Although all measures to protect confidentiality will be put in place, the possibility exists that electronic data could be jeopardized. In the remote case that such event occurs, it will be immediately reported to the IRB.
No substantial psychological, medical, or social risks exist to the participants, other than minor discomfort associated with the venipuncture. The components of everycell should be harmless without significant food allergies. No serious, untoward side effects have been reported to the company by consumers nor observed during previous human studies. If any side effect does occur, the remedy is to discontinue until asymptomatic, and then reintroduce at 1/4 dosage, increasing by the same amount every 2 days, if uneventful, until full dosage is achieved. A toxicology search for each component reveals no unique toxicity characteristic of the materials. As reported by CellHealth Institute, the manufacturer of the product, many customers currently use Everycell, and CellHealth Institute is unaware of significant toxicities.
CellHealth Institute applies the latest scientific methods to ensure the value and safety of their raw materials. CellHealth Institute products are manufactured in state-of-the-art facilities, under strict quality control and environmental protection standards.
Participants will incur no additional appreciable psychological or social risks by participating in this study, although they may undergo psychological and physical discomfort sometimes. The process of interviewing during the assessment may cause discomfort. Discomfort or fatigue may also be experienced in completing the assessment battery.
Alternatives to this study for improving DNA damage, inflammation, and stress include prescription medications, exercise, dietary modification, and other nutritional supplements. The risks of medications can be very significant, including life-threatening, but the risk of taking nutritional supplements is not totally understood, since they are not regulated by the US Food and Drug Administration. Medications and nutritional supplements, as part of a change in lifestyle behaviors, may also prove to be beneficial for DNA damage, inflammation, and stress, but their long-term use has unknown consequences.
The information obtained in this study will help in determining the efficacy of using a nutritional supplement for improving DNA damage, inflammation, and stress outcomes. By participating in the study, subjects may experience improved DNA damage, inflammation, and stress. The risk of participating in this study is reasonable because of the potential enhancements in DNA damage, inflammation, and stress with improved nutritional status.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Miller School of Medicine, Clinical Research Building
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be between the ages of 18 and 55
- Live independently without medical assistance
- Willing to provide informed consent to participate in the study
Willing to follow our procedures and requirements for the study, including:
- providing blood, urine, and saliva samples
- completing other assessments
- Patients may take a similar dietary supplement as the one used in the study, but they must stop taking all similar dietary supplements 2 weeks prior to starting the study and for the 6 weeks duration of the study.
Exclusion Criteria:
- Patients need to be free of major medical conditions, such as neurological, cardiovascular, pulmonary, renal, endocrine, thyroid, hepatic, autoimmune, or bone/joint disorders or conditions; psychiatric diagnoses or psychotic disorders, and have no gastrointestinal disorders that could affect how the dietary supplement is absorbed by their body.
- Cannot participate in another similar research trial within 30 days of participating in this study
- Cannot be a smoker or have stopped smoking less than 6 months ago
- Cannot currently be taking any chemotherapy or radiation treatment for cancer
- Cannot be diagnosed with a terminal illness
- Cannot be diagnosed with insulin-dependent diabetes and/or be taking metformin
- Cannot be HIV positive
- If female, the patient cannot currently be pregnant, breastfeeding, or intending to become pregnant within the next month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Everycell™
Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
|
|
Placebo Comparator: Placebo
Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in Fructosamine at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in Protein Thiol Test at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in Homocysteine at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in Telomere Length at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in Cluster of Differentiation 4 (Regulatory T-cell) at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in Cluster of Differentiation 8 at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in Cluster of Differentiation 56 (Natural Killer cell) at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in 8-hydroxydeoxyguanosine at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Urine sample for 8-OHdG and 8-epi-PGF-2-alpha
|
Baseline, 4-week follow-up
|
Change from Baseline in 8-epi-PGF-2-alpha at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Urine sample for 8-OHdG and 8-epi-PGF-2-alpha
|
Baseline, 4-week follow-up
|
Change from Baseline in Forkhead box protein 3 (Regulatory T-cell) at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 4-week follow-up
|
Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in Fructosamine at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in Protein Thiol Test at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in Homocysteine at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in Telomere Length at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in Cluster of Differentiation 4 (Regulatory T-cell) at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in Cluster of Differentiation 8 at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in Cluster of Differentiation 56 (Natural Killer cell) at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in 8-hydroxydeoxyguanosine at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in 8-epi-PGF-2-alpha at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Change from Baseline in Forkhead box protein 3 (Regulatory T-cell) at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
|
Baseline, 6-week follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Systolic Blood Pressure at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Systolic and diastolic blood pressure measured.
|
Baseline, 4-week follow-up
|
Change from Baseline in Pulse at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Baseline, 4-week follow-up
|
|
Change from Baseline in Waist Circumference at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Measure of body composition: waist circumference (cm).
|
Baseline, 4-week follow-up
|
Change from Baseline in Hip Circumference at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Measure of body composition: hip circumference (cm).
|
Baseline, 4-week follow-up
|
Change from Baseline in Weight at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Measure of body composition: weight.
|
Baseline, 4-week follow-up
|
Change from Baseline in Height at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Measure of body composition: height.
|
Baseline, 4-week follow-up
|
Change from Baseline in Body Mass Index at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Measure of body composition: height and weight to assess BMI.
|
Baseline, 4-week follow-up
|
Change from Baseline in International Physical Activity Questionnaire at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Baseline, 4-week follow-up
|
|
Change from Baseline in SF-36v2™ Health Survey at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Baseline, 4-week follow-up
|
|
Change from Baseline in Systolic Blood Pressure at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Systolic and diastolic blood pressure measured.
|
Baseline, 6-week follow-up
|
Change from Baseline in Diastolic Blood Pressure at 4 weeks
Time Frame: Baseline, 4-week follow-up
|
Systolic and diastolic blood pressure measured.
|
Baseline, 4-week follow-up
|
Change from Baseline in Diastolic Blood Pressure at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Systolic and diastolic blood pressure measured.
|
Baseline, 6-week follow-up
|
Change from Baseline in Pulse at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Baseline, 6-week follow-up
|
|
Change from Baseline in Waist Circumference at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Measure of body composition: waist circumference (cm).
|
Baseline, 6-week follow-up
|
Change from Baseline in Hip Circumference at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Measure of body composition: hip circumference (cm).
|
Baseline, 6-week follow-up
|
Change from Baseline in Weight at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Measure of body composition: weight.
|
Baseline, 6-week follow-up
|
Change from Baseline in Height at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Measure of body composition: height.
|
Baseline, 6-week follow-up
|
Change from Baseline in Body Mass Index at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Measure of body composition: height and weight to assess BMI.
|
Baseline, 6-week follow-up
|
Change from Baseline in International Physical Activity Questionnaire at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Baseline, 6-week follow-up
|
|
Change from Baseline in SF-36v2™ Health Survey at 6 weeks
Time Frame: Baseline, 6-week follow-up
|
Baseline, 6-week follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20130411 (Other Identifier: Amgen Study ID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Family Member
-
University of MiamiCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...Active, not recruitingFamily Member | Health Status UnknownUnited States
-
University of MiamiBiotics, Inc.Completed
-
Assistance Publique Hopitaux De MarseilleCompletedImprove the Understanding of the Diagnosis the Treatment and the Prognosis by One Member of the FamilyFrance
-
Rockefeller UniversityCompletedSubjects Will Have a Pre-cancerous Colorectal Polyp | Family Member Has History of Colorectal Adenoma of AdenocarcinomaUnited States
-
Tommaso GoriCompletedExposure of Member of Staff to Medical Diagnostic X-RayGermany
-
Eva Morava-KoziczNot yet recruitingSLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of GlycosylationUnited States
-
Stockholm UniversityRecruitingFamily Relations | Family Conflict | Family DysfunctionSweden
-
The University of Hong KongTung Wah Group of HospitalsCompletedParenting | Family | Family Research
-
Montefiore Medical CenterChildren's Bureau - Administration for Children and FamiliesRecruitingParenting | Family Relations | Relationship, FamilyUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States